(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...

Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi. The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in ...

Struggling Novavax struck a $1.4 billion deal with Sanofi on Friday to commercialize its existing COVID-19 vaccine and develop a combined jab to protect against both the coronavirus and influenza ...

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...

Gaithersburg’s Novavax says it will have an updated Covid-19 vaccine ready after an FDA committee voted unanimously on the ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that ...

Novavax (NASDAQ:NVAX) shares hit a 52-week high on Friday as the COVID-19 vaccine maker removed its going-concern notice with its Q1 2024 financials on the back of a licensing deal with Sanofi ...

Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced Friday. Through ...

Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B. Riley Securities Managing Director & Group Head of Healthcare Research ...

(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from ...